Lesinurad and Allopurinol Combination Extension Study in Gout

Inclusion Criteria

• •Subject is able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first study related activity.
• •Subject completed the double-blind treatment period in either Study RDEA594-301 or RDEA594-302 and was actively receiving and tolerating study medication (lesinurad or placebo) and allopurinol at the Month 12 visit.
• •Subject is male or female; female subjects of childbearing potential must agree to use an effective non-hormonal method of birth